Blueprint
Exhibit 99.1
8229
Boone Boulevard, Suite 802
Vienna,
VA 22182. USA
Telephone
(703) 506-9460
www.cel-sci.com
|
COMPANY
CONTACT:
Gavin
de Windt
CEL-SCI
Corporation
(703)
506-9460
|
CEL-SCI ANNOUNCES ADJUSTMENT TO WARRANT EXERCISE PRICE
Vienna, VA, January 16, 2018 – CEL-SCI Corporation
(NYSE American: CVM)
announced today that the outstanding Series S warrants (CUSIP
number 150837177) that are publicly traded under the symbol
“CVM WS” on the NYSE American have been repriced to
$3.00 per share of common stock for a three month period which will
end on April 12, 2018. After this date, the exercise price will
revert back to $31.25 per share of common stock. As a result of the
reverse stock split which became effective on the NYSE American on
June 15, 2017, 25 warrants are required to purchase one share of
common stock. The warrants expire on October 11, 2018.
About CEL-SCI Corporation
CEL-SCI
is a Phase 3 cancer immunotherapy company. When it comes to cancer
immunotherapy, CEL-SCI believes it is most logical to boost the
patient’s immune system while it is still intact in order to
have the greatest possible impact on survival. Therefore, CEL-SCI
treats patients who are newly diagnosed with head and neck cancer
with its lead investigational immunotherapy Multikine* (Leukocyte
Interleukin, Injection), BEFORE they have received surgery,
radiation and/or chemotherapy, at a time when the immune system
should be at its strongest. This approach is unique. Most other
cancer immunotherapies are used only after conventional therapies
have been tried and/or failed. Head and neck cancer represents
about 6% of all cancers. Multikine has received Orphan Drug
designation from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma.
The Company’s LEAPS technology is being developed as a
potential therapeutic vaccine for rheumatoid arthritis and is
supported by a grant from the National Institute of
Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability
to duplicate the clinical results demonstrated in clinical studies,
timely development of any potential products that can be shown to
be safe and effective, receiving necessary regulatory approvals,
difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI’s filings with
the Securities and Exchange Commission, including but not limited
to its report on Form 10-K for the year ended September 30, 2017.
The Company undertakes no obligation to publicly release the result
of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof
or to reflect the occurrence of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.